READ MOREAkston Biosciences Completes Series D Preferred Stock Financing

READ MOREAkston Biosciences Ends Vaccine Partnership with Stelis, Continues to Advance COVID Universal Booster EUA

READ MOREAkston Biosciences Announces Positive Interim Phase II Results from COVID “Universal” Booster Vaccine Trial

READ MOREAkston Biosciences Receives U.S. Patent for Once-A-Week Human Insulin

READ MOREBiolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine

READ MOREAkston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster

READ MOREAkston Biosciences CEO to Present at the World Vaccine Congress

READ MOREAkston Biosciences Doses First Volunteers in Phase II/III Clinical Trial of Low Cost, Shelf Stable COVID-19 Vaccine

READ MOREAkston Biosciences Receives Regulatory Approval for Phase II Clinical Trial for Shelf-Stable COVID-19 Vaccine Booster

READ MOREAkston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries